Probiotics for Children With Recurrent Abdominal Pain

Newlove‐Delgado, Tamsin; Abbott, Rebecca; Martin, Alice

doi:10.1001/jamapediatrics.2018.4575

Cited by 12 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…109 Probiotic preparations may improve abdominal pain in children in the short term. 114 However, another randomised, double-blind, placebo-controlled trial found that Saccharomyces cerevisiae CNCM I-3856 at a dose of 1 g day À1 does not improve intestinal pain and discomfort in patients with general IBS. 110 A multicentre, randomised, double-blind, placebo-controlled, crossover trial looking at a probiotic mixture of B. infantis M-63, B. breve M-16V, and B. longum BB536 demonstrated improved abdominal pain and quality of life in children with IBS.…”

Section: Probiotics Prebiotics and Synbioticsmentioning

confidence: 99%

Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential

Guo

Chen²,

Chen

et al. 2019

British Journal of Anaesthesia

266

208

View full text Add to dashboard Cite

The relationship between gut microbiota and neurological diseases, including chronic pain, has received increasing attention. The gut microbiome is a crucial modulator of visceral pain, whereas recent evidence suggests that gut microbiota may also play a critical role in many other types of chronic pain, including inflammatory pain, headache, neuropathic pain, and opioid tolerance. We present a narrative review of the current understanding on the role of gut microbiota in pain regulation and discuss the possibility of targeting gut microbiota for the management of chronic pain. Numerous signalling molecules derived from gut microbiota, such as by-products of microbiota, metabolites, neurotransmitters, and neuromodulators, act on their receptors and remarkably regulate the peripheral and central sensitisation, which in turn mediate the development of chronic pain. Gut microbiota-derived mediators serve as critical modulators for the induction of peripheral sensitisation, directly or indirectly regulating the excitability of primary nociceptive neurones. In the central nervous system, gut microbiota-derived mediators may regulate neuroinflammation, which involves the activation of cells in the bloodebrain barrier, microglia, and infiltrating immune cells, to modulate induction and maintenance of central sensitisation. Thus, we propose that gut microbiota regulates pain in the peripheral and central nervous system, and targeting gut microbiota by diet and pharmabiotic intervention may represent a new therapeutic strategy for the management of chronic pain.

show abstract

Section: Probiotics Prebiotics and Synbioticsmentioning

confidence: 99%

Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential

Guo

Chen²,

Chen

et al. 2019

British Journal of Anaesthesia

266

208

View full text Add to dashboard Cite

show abstract

“…A well-maintained gut microbiota diversity is essential for a normal life, whereas alterations to it (dysbiosis) have impacts on the gut-brain axis, leading to a variety of neurological diseases, such as neuropsychiatric disorders ( Ochoa-Repáraz et al, 2020 ; Ni et al, 2021 ). Gut microbiota alterations are also noticed in patients suffering from different types and areas of chronic pain, including visceral pain, inflammatory pain, headache, neuropathic pain, and chronic widespread pain ( Newlove-Delgado et al, 2019 ; Yang et al, 2019 ; Chen et al, 2020 ; Guida et al, 2020 ; Freidin et al, 2021 ). Based on these studies, we believe that two possibilities should not be neglected: one is that chronic pain may lead to dysbiosis, and the other is that gut microbiota may be a possible way to regulate chronic pain conditions.…”

Section: Introductionmentioning

confidence: 99%

Gut microbiota alterations may increase the risk of prescription opioid use, but not vice versa: A two-sample bi-directional Mendelian randomization study

Lin

Qiu

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

IntroductionGut microbiota alterations are strongly associated with prescription opioid use (POU) and multisite chronic pain (MCP). However, whether or not these associations are causal remains unknown. Therefore, we aim to explore the causal relationships between them comprehensively.MethodsA two-sample bi-directional Mendelian randomization was conducted to assess the potential associations between gut microbiota and POU/MCP using summary level Genome-wide association studies (GWASs) that were based on predominantly European ancestry.ResultsPotential causal effects were identified between seven host genetic-driven traits of gut microbiota on POU, including Adlercreutzia, Allisonella, Dialister, Anaerofilum, Anaerostipes, ChristensenellaceaeR.7group, and LachnospiraceaeNC2004group at the genus level (p < 0.05) by the Inverse-variance weighted method, with significant causal effects of ChristensenellaceaeR.7group and Allisonella on POU (p < 0.025). A total of five genetically greater abundance of gut microbiota traits were identified to be possibly related to the level of MCP (p < 0.05), including genus ErysipelotrichaceaeUCG003, family Clostridiaceae1, order Gastranaerophilales, order Actinomycetales, and family Actinomycetaceae. In the other direction, no clear evidence was found to support a significant causal relationship between POU and gut microbiota, as well as MCP and gut microbiota. In addition, evidence was also provided for the relationship between triacylglycerols and diacylglycerol elevation, and an increased risk of POU and MCP. No evidence was found across various sensitivity analyses, including reverse causality, pleiotropy, and heterogeneity.ConclusionThe findings from this study provide robust evidence that gut microbiota alterations may be a risk of POU/MCP, but not vice versa.

show abstract

“…Likewise, the intervention group noted the markedly higher quality of life improvement in comparison with a placebo (48% vs. 17%, p = 0.001) [ 150 ]. A 2009 review by Newlove-Delgado et al retrospectively investigating the use of probiotics in children with recurrent abdominal pain suggested that those preparations are likely to improve pain symptoms in the short term, that is, up to 3 months (OR = 1.63; 95% CI = 1.07–2.47) [ 151 ]. By contrast, a randomized, placebo-controlled trial by Spiller et al failed to identify any clinical benefit, including intestinal pain and discomfort, of S. cerevisiae I-3856 supplementation at a dose of 1000 mg per day, in comparison to a placebo [ 152 ].…”

Section: The Gut Microbiota As a Therapeutic Target In Chronic Painmentioning

confidence: 99%

The Role of the Human Microbiome in the Pathogenesis of Pain

Ustianowska

Ustianowski

Machaj

et al. 2022

IJMS

View full text Add to dashboard Cite

Understanding of the gut microbiome’s role in human physiology developed rapidly in recent years. Moreover, any alteration of this microenvironment could lead to a pathophysiological reaction of numerous organs. It results from the bidirectional communication of the gastrointestinal tract with the central nervous system, called the gut–brain axis. The signals in the gut–brain axis are mediated by immunological, hormonal, and neural pathways. However, it is also influenced by microorganisms in the gut. The disturbances in the gut–brain axis are associated with gastrointestinal syndromes, but recently their role in the development of different types of pain was reported. The gut microbiome could be the factor in the central sensitization of chronic pain by regulating microglia, astrocytes, and immune cells. Dysbiosis could lead to incorrect immune responses, resulting in the development of inflammatory pain such as endometriosis. Furthermore, chronic visceral pain, associated with functional gastrointestinal disorders, could result from a disruption in the gut microenvironment. Any alteration in the gut–brain axis could also trigger migraine attacks by affecting cytokine expression. Understanding the gut microbiome’s role in pain pathophysiology leads to the development of analgetic therapies targeting microorganisms. Probiotics, FODMAP diet, and fecal microbiota transplantation are reported to be beneficial in treating visceral pain.

show abstract

Probiotics for Children With Recurrent Abdominal Pain

Cited by 12 publications

References 7 publications

Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential

Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential

Gut microbiota alterations may increase the risk of prescription opioid use, but not vice versa: A two-sample bi-directional Mendelian randomization study

The Role of the Human Microbiome in the Pathogenesis of Pain

Contact Info

Product

Resources

About